ZEAL   $17.59  -0.96% Market Closed

Zealand Pharma A/S
Last Events:

2023-03-29 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-03-29 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: entrance to the overbought zone.

2023-03-28 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-03-28 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: entrance to the overbought zone.

2023-03-27 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-03-27 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: entrance to the overbought zone.

2023-03-26 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-03-26 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: entrance to the overbought zone.


Current temperature: 1.89
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 14.00
Target: 35.63
High with 50% probability: 26.05
Analyst Recommendations:
Number of estimates 2
Target Price Mean 35.19
Mean unverified/preliminary 35.19 / 35.19
Target Price Low / High 35.19 / 35.19
Median / STD DEV 35.19 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd Sell Sell -
stoch Sell Sell -
ma20 - - -
ma50 - - -
ma100 - - -
Candlestick PatternSept. 21, 2022 Bullish Belt Hold - is a candlestick that has a long white body and small shadows. It opens on the low of the day. It occurs in a downtrend. Considered to be a bullish reversal pattern.
ISIN US98920Y3045
ceo Mr. Adam Sinding Steensberg M.D.
Website https://www.zealandpharma.com
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.